Mark Christopher Capone net worth and biography

Mark Capone Biography and Net Worth

Director of Mesa Laboratories

Mr. Capone most recently served as CEO and President of Myriad Genetics for five years. Prior to his appointment as CEO and President, he held various progressive leadership roles at Myriad Genetics, with a total tenure of 17 years at the company. During his leadership tenure, he oversaw Myriad Genetics’ growth from an early-stage pioneer in molecular diagnostics into a leading global precision medicine company. Prior to his tenure at Myriad Genetics, Mr. Capone spent 17 years with Eli Lilly and Company in positions across the entire value chain.

In addition to his executive leadership positions, Mr. Capone is a Non-Executive Director and member of the Compensation Committee for of Owlstone Medical Ltd, a breath biopsy diagnostic company focused on early detection of cancer and precision medicine, and a Non-Executive Director and member of the Audit Committee and Financing Committee of DermTech, a U.S. based company focused on early melanoma detection and other skin applications. Previously, Mr. Capone was a director at Abcam PLC, helping to guide that company through its acquisition by Danaher Corporation. Mr. Capone holds a Bachelor of Science in Chemical Engineering from Pennsylvania State University and a M.Sc. in Management and a M.Sc.in Chemical Engineering from Massachusetts Institute of Technology.

What is Mark Christopher Capone's net worth?: The estimated net worth of Mark Christopher Capone is at least $280.46 thousand as of March 10th, 2026. Capone owns 3,429 shares of Mesa Laboratories stock worth more than $280,458 as of March 27th. This net worth estimate does not reflect any other assets that Capone may own. Learn More about Mark Christopher Capone's net worth.
How do I contact Mark Christopher Capone?: The corporate mailing address for Capone and other Mesa Laboratories executives is 12100 W 6TH AVE, LAKEWOOD CO, 80228. Mesa Laboratories can also be reached via phone at (303) 987-8000 and via email at [email protected]. Learn More on Mark Christopher Capone's contact information.
Has Mark Christopher Capone been buying or selling shares of Mesa Laboratories?: Within the last three months, Mark Christopher Capone has bought $99,331.35 of Mesa Laboratories stock. Most recently, on Tuesday, March 10th, Mark Christopher Capone bought 1,301 shares of Mesa Laboratories stock. The stock was acquired at an average cost of $76.35 per share, with a total value of $99,331.35. Following the completion of the transaction, the director now directly owns 3,429 shares of the company's stock, valued at $261,804.15. Learn More on Mark Christopher Capone's trading history.
Who are Mesa Laboratories' active insiders?: Mesa Laboratories' insider roster includes Brian Archbold (SVP), Mark Capone (Director), Gregory DiNoia (SVP), Evan Guillemin (Director), David Kelly (Director), Gary Owens (CEO), John Sakys (CFO), John Schmieder (Director), and John Sullivan (Director). Learn More on Mesa Laboratories' active insiders.
Are insiders buying or selling shares of Mesa Laboratories?: During the last twelve months, Mesa Laboratories insiders bought shares 3 times. They purchased a total of 6,116 shares worth more than $452,076.35. During the last twelve months, insiders at the medical instruments supplier sold shares 3 times. They sold a total of 3,053 shares worth more than $296,507.36. The most recent insider tranaction occured on March, 10th when Director Mark Christopher Capone bought 1,301 shares worth more than $99,331.35. Insiders at Mesa Laboratories own 4.9% of the company. Learn More about insider trades at Mesa Laboratories.
Information on this page was last updated on 3/10/2026.

Mark Christopher Capone Insider Trading History at Mesa Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2026	Buy	1,301	$76.35	$99,331.35	3,429

Mark Christopher Capone Buying and Selling Activity at Mesa Laboratories

Mesa Laboratories Company Overview

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Today's Range

Now: $82.47

$81.68

$82.45

50 Day Range

MA: $86.58

$73.23

$96.57

2 Week Range

Now: $82.47

$55.45

$131.20

Volume

15,433 shs

Average Volume

107,764 shs

Market Capitalization

$455.23 million

P/E Ratio

128.86

Dividend Yield

0.77%

Beta

0.85